| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
BioLife Solutions, Inc.$33.93
+0.13 (+0.38%)
Market Cap
1.66 B
EPS
-0.06
P/E Ratio
-
Value Trade
23.08 M
SEC Financials
Q1 2026Dilution Risk
Revenue
27.50 M
R&D Expenses
2.65 M
Operating CF
-491.00 K
Total Assets
400.91 M
Total Liabilities
28.68 M
Equity
372.23 M
7.24 %
Week
21.48 %
1 Month
46.76 %
3 Month
54.09 %
6 Month
-28.03 %
5 Year
-78.1 %
All Time
Cash Data
Cash Position
81.00 M
Monthly Burn
164.00 K
Runway
490.9 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
461.48 K
52 Week Range
17.86 - 33.84
% held by Insiders
4.1 %
% held by Institutions
99.65 %
Enterprise Value
1.58 B
Total Shares
48.88 M
Short %
6.09 %
Float Shares
47.36 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Cx601 | complex perianal fistula in Crohn's Disease patients | Phase 3 | 2015-08-31 | More than 50% of patients treated with Cx601 achieved combined remission at week 24; A higher number of Cx601-treated patients had their fistulas closed by week 6 Read More | BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint Read More | |
Cx601 | complex perianal fistula in Crohn's Disease patients | Phase 3 | 2015-08-31 | More than 50% of patients treated with Cx601 achieved combined remission at week 24; A higher number of Cx601-treated patients had their fistulas closed by week 6 Read More | BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint Read More | |
Cx601 | complex perianal fistula in Crohn's Disease patients | Phase 3 | 2015-08-31 | More than 50% of patients treated with Cx601 achieved combined remission at week 24; A higher number of Cx601-treated patients had their fistulas closed by week 6 Read More | BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BLFS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BLFS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BLFS▲ +0.4%today
BioLife Solutions Reports Second Quarter 2026 Financial Results
BioLife Solutions reported strong financial results for Q2 2026, with total revenue reaching $28.5 million, marking a 21% increase from the same period last year. The company also announced a planned acquisition by Repligen, expected to close in Q4 2026. BioLife's biopreservation media continues to play a crucial role in the cell and gene therapy market, utilized in numerous clinical trials.
Read more →BLFS▲ +6.7%on this news
Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media
Repligen Corporation has announced its acquisition of BioLife Solutions for approximately $1.5 billion, aimed at enhancing its capabilities in the cell therapy market. The deal, which includes both cash and stock components, is expected to be accretive to Repligen's earnings and broaden its customer solutions. The transaction is anticipated to close in Q4 2026, subject to regulatory approvals.
Read more →BLFSBioLife and Qkine Partner to Streamline Cell and Gene Therapy Workflows
BioLife Solutions has partnered with Qkine Limited to improve access to animal-free cytokines and growth factors for cell and gene therapy workflows. This collaboration aims to enhance process control and scalability in various therapeutic areas, including cancer immunotherapy and regenerative medicine. BioLife will distribute Qkine's products, which are designed to meet high-quality standards, ensuring better consistency and reduced contamination risks.
Read more →BLFSRegister Now for The Cell Summit ’26
The Cell Summit '26, scheduled for July 28-29, 2026, in Cincinnati, Ohio, focuses on overcoming practical challenges in cell and gene therapy. Organized by BioLife Solutions and Cincinnati Children's Hospital, the event will facilitate collaboration among industry leaders to enhance manufacturing, delivery, and clinical implementation of therapies. Discussions will cover various critical aspects of the cell therapy workflow.
Read more →BLFSBioLife Solutions Reports First Quarter 2026 Financial Results
BioLife Solutions reported a strong financial performance for Q1 2026, with total revenue reaching $27.5 million, a 25% increase from the previous year. The company achieved a GAAP net income of $1.2 million and an adjusted EBITDA of $6.2 million, representing 22% of revenue. CEO Roderick de Greef highlighted ongoing demand for their products and confidence in future growth.
Read more →BLFSBioLife Solutions to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
BioLife Solutions, Inc. will release its first quarter 2026 financial results on May 7, 2026. The company will host a conference call and live webcast at 4:30 PM ET to discuss the results and provide a business update. Investors can access the call through the company's website or by phone.
Read more →BLFSBioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal® CryoCase
BioLife Solutions has been awarded the INTERPHEX 2026 Biotech Innovation Award for its CellSeal® CryoCase, designed to improve the containment of frozen biologic materials. The CryoCase addresses issues with traditional cryobags, such as stress fractures and seal fatigue, enhancing reliability during the freezing and storage processes. This recognition underscores the importance of innovation in the cell and gene therapy market.
Read more →BLFSSanguine Bio Standardizes on CryoStor® to Support Consistent PBMC Cryopreservation
Sanguine Bio has standardized its PBMC cryopreservation process using BioLife Solutions' CryoStor. This decision aims to enhance the quality and consistency of biospecimens for translational research. CryoStor CS10, a defined cryopreservation medium, is noted for maintaining cellular integrity and viability. This move reflects a broader trend towards rigorous biospecimen workflows.
Read more →BLFS▲ +7.7%on this news
BioLife Solutions Reports Fourth Quarter and Full Year 2025 Financial Results from Continuing Operations
BioLife Solutions reported a strong financial performance for the fourth quarter and full year of 2025, with revenues increasing by 29% year-over-year. The company achieved a GAAP net income of $2.1 million for Q4 and anticipates further growth in 2026, projecting revenues between $112.5 million and $115 million. The CEO highlighted the company's strategic focus on cell processing tools and services for the cell and gene therapy market.
Read more →BLFSHow Early Supplier Partnership Strategies Support Cell Therapy Approvals
The article discusses the importance of early supplier partnerships in the regulatory readiness of cell therapies. It highlights how these collaborations can streamline the approval process by addressing manufacturing and biopreservation strategies early on. The FDA's focus on consistent manufacturing and operational discipline is emphasized, suggesting that proactive partnerships can significantly reduce risks and enhance the likelihood of successful approvals.
Read more →BLFSBioLife Solutions to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 26, 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) announced that it will release its fourth quarter and full year 2025 financial results on February 26, 2026. The company will also host a conference call and live webcast to discuss the financial results and provide a business update. Investors can access the call through the company's website or by phone. BioLife Solutions is recognized for its contributions to the cell and gene therapy market.
Read more →BLFSBioLife Solutions Signs Multi-Year Supply Agreement with Qkine Limited to Expand its Product Portfolio into the Rapidly Growing Cytokines Market
BioLife Solutions has signed a multi-year supply agreement with Qkine Limited to distribute cytokine and growth factor products for cell and gene therapy manufacturing. This agreement grants BioLife exclusive worldwide distribution rights for specific Qkine products and includes a collaboration on product development using BioLife's CellSeal®Connect vial system. The global cytokines market is expected to grow significantly, providing a strategic opportunity for BioLife.
Read more →BLFSAdvancing Cell and Gene Therapy Manufacturing Through Collaboration: BioLife Partners with ScaleReady and the Emily Whitehead Foundation
BioLife Solutions has partnered with ScaleReady and the Emily Whitehead Foundation to launch the G-Rex Grant Tour, starting January 21, 2026. This initiative aims to enhance cell and gene therapy (CGT) manufacturing through education and collaboration across major U.S. cities. The tour will address practical challenges in CGT development and provide resources to accelerate therapy access for patients.
Read more →BLFSBioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2025 Unaudited Revenue from Continuing Operations
BioLife Solutions reported a preliminary fourth quarter revenue of $24.8 million for 2025, reflecting a 20% increase over the previous year. The full year revenue reached $96.2 million, surpassing the company's earlier raised guidance. The growth was primarily driven by the biopreservation product line. CEO Roderick de Greef expressed optimism for 2026, expecting further revenue growth and expansion of the adjusted EBITDA margin. However, the results are preliminary and subject to final adjustments.
Read more →BLFSPreserving the Promise™—Together
BioLife Solutions has unveiled a brand refresh aimed at enhancing the cell and gene therapy (CGT) community. The updated identity focuses on clarity, trust, and standardization, facilitating better partnerships and outcomes. The launch of the Aby J. Mathew Center for Biopreservation Excellence aims to foster collaboration among industry experts, ultimately preserving the promise of therapies for patients.
Read more →BLFSBioLife Solutions Unveils the Aby J. Mathew Center for Biopreservation Excellence
BioLife Solutions has inaugurated the Aby J. Mathew Center for Biopreservation Excellence at its Bothell headquarters. Named after a founding team member, the center aims to advance biopreservation and cell processing through research, training, and collaboration. It features modern facilities to optimize biopreservation processes and support the development of new cryopreservation products.
Read more →BLFSBioLife Solutions to Participate in Upcoming Investor Conferences in November and December 2025
BioLife Solutions, Inc. announced its participation in upcoming investor conferences in November and December 2025. The company is a prominent developer of bioproduction products for the cell and gene therapy market. Their investor presentation, featuring a refreshed corporate branding, is available on their website, highlighting their commitment to investor engagement.
Read more →BLFSBioLife Solutions Reports Third Quarter 2025 Financial Results
BioLife Solutions reported a strong third quarter for 2025, with a 33% increase in Cell Processing revenue compared to the previous year. The company also raised its full-year revenue guidance, projecting total revenues between $95 million and $96 million. CEO Roderick de Greef highlighted the company's focus on core cell processing business and profitability improvements. The conference call for further discussion is scheduled for later today.
Read more →BLFSBiopreservation Is Critical. Start with the Team That Wrote the Playbook.
The article discusses the critical role of biopreservation in cell and gene therapy manufacturing, emphasizing the need for expertise in cryobiology. It highlights the challenges posed by a shortage of trained professionals and the importance of partnering with experienced providers like BioLife Solutions. The article also introduces key figures in the field and their contributions to advancing biopreservation methods.
Read more →BLFSBioLife Solutions to Report Third Quarter 2025 Financial Results and Business Update on November 6, 2025
BioLife Solutions, Inc. will release its third quarter 2025 financial results on November 6, 2025. A conference call and live webcast will be held on the same day at 4:30pm ET to discuss the financial results and provide a business update. The company, known for its bioproduction products and services in the cell and gene therapy market, aims to enhance the commercialization of new therapies through its offerings.
Read more →BLFSBioLife Solutions Announces the Sale of its evo Cold Chain Logistics Subsidiary
BioLife Solutions, Inc. has announced the sale of its cold chain logistics subsidiary, SAVSU Cleo Technologies, for $25.5 million in cash to Peli BioThermal. This divestiture aims to streamline BioLife's product portfolio and operations, allowing the company to focus on generating high-margin recurring revenue. CEO Roderick de Greef expressed satisfaction with the transaction, highlighting the value of SAVSU's technology.
Read more →BLFSThe Silent Threat in Cell Therapy Development: Transient Warming Events
The article discusses the critical issue of Transient Warming Events (TWEs) in cell therapy, highlighting their potential to compromise cell viability and therapeutic outcomes. Experts at The Cell Summit 2025 emphasized the need for improved monitoring and management practices to mitigate the risks associated with TWEs. Solutions such as Ice Recrystallization Inhibitors (IRIs) were presented as effective means to preserve cell quality during temperature fluctuations. The overall consensus is that while TWEs pose significant challenges, they are preventable with the right strategies.
Read more →BLFSBioLife Solutions Reports Second Quarter 2025 Financial Results
BioLife Solutions reported its financial results for Q2 2025, demonstrating strong growth with a 28% increase in cell processing revenue. The company raised its full-year revenue guidance to between $100 million and $103 million amid continued demand for its biopreservation media, which is currently embedded in several commercial therapies and ongoing trials. However, the report noted a GAAP net loss of $15.8 million, largely due to a non-cash charge from an acquired technology. Despite this loss, adjusted EBITDA showed improvement, indicating operational efficiencies within the company.
Read more →BLFSBioLife Solutions Makes Strategic Investment in Pluristyx
BioLife Solutions has invested $2 million in convertible notes for Pluristyx, a Seattle-based developer of induced pluripotent stem cell products. This investment includes a board observer seat and rights related to future acquisitions. Both companies have a history of collaboration, and BioLife's CEO expressed confidence in Pluristyx's scientific expertise.
Read more →BLFSBioLife Solutions to Report Second Quarter 2025 Financial Results and Business Update on August 7, 2025
BioLife Solutions, Inc. will release its second quarter 2025 financial results on August 7, 2025, after market close. The company will also host a conference call and live webcast at 4:30 PM ET to discuss the results and provide a business update. Investors can access the call through the company's website or by phone.
Read more →BLFSThe Cell Summit ’25 Frequently Asked Questions (FAQs)
The Cell Summit '25 is set to take place at Newfields Art Museum in Indianapolis, offering attendees a well-organized schedule with meals included. The event features presentations, networking opportunities, and a baseball game for social engagement. Shuttle services will facilitate transportation between the JW Marriott and the event venue.
Read more →BLFSMeet the Makers: Innovations and Insights from The Cell Summit ’25
The Cell Summit '25, hosted by BioLife Solutions, will take place in August in Indianapolis, gathering leaders from the cell and gene therapy industry. The event will feature presentations from various experts discussing topics such as biopreservation, automation, and regulatory strategies. Attendees will have the opportunity to engage with thought leaders and explore innovations shaping CGT manufacturing.
Read more →BLFSDesigning the Ideal Cryostorage Container for CGT
The CellSeal CryoCase, launched at the 2024 ISCT Annual Meeting, has become a key solution for CGT storage. Designed by Adam Shields, it offers enhanced durability and reduces contamination risks compared to traditional cryobags. One year post-launch, studies confirm its superior performance in maintaining cell viability and operational efficiency.
Read more →BLFSBioLife Solutions to Participate in Upcoming Investor Conferences in May and June 2025
BioLife Solutions, Inc. announced its participation in several investor conferences scheduled for May and June 2025. These conferences include the 22nd Annual Craig-Hallum Institutional Investor Conference, the Benchmark 2025 Healthcare House Call Virtual Conference, the Jefferies Global Life Sciences Conference, and the Wolfe Research Small & Mid-Cap Conference. This involvement underscores the company's efforts to engage with investors and showcase its innovations in bioproduction for the cell and gene therapy market.
Read more →BLFSBioLife Solutions Updates Earnings Call Information
BioLife Solutions, Inc. has announced corrected call-in numbers for its upcoming Earnings Call scheduled for 4:30 PM ET. This update aims to ensure that participants can easily join the call. BioLife is recognized for its contributions to the cell and gene therapy market, providing essential tools and services.
Read more →BLFSBioLife Solutions Reports First Quarter 2025 Financial Results
BioLife Solutions, Inc. has reported first quarter 2025 financial results, showcasing a 30% increase in total revenue compared to Q1 2024. The company's Cell Processing revenue saw a notable 33% growth, indicating strong demand driven by its biopreservation media product line. BioLife completed the acquisition of PanTHERA CryoSolutions, enhancing its capabilities in cryopreservation. Despite a small net loss, management remains optimistic about financial guidance for the year, projecting revenue growth of 16% to 20% compared to 2024.
Read more →BLFSBioLife Solutions to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
BioLife Solutions, Inc. will release its first quarter 2025 financial results on May 8, 2025, after market close. The company will host a conference call and live webcast at 4:30 PM ET to discuss the results and provide a business update. Investors can access the call through the company's website or by phone.
Read more →BLFSThe Cell Summit ’25: A Must-Attend Event for Innovators in Cell & Gene Therapy
The Cell Summit '25, scheduled for August 5-6 at Newfields Art Museum in Indianapolis, aims to unite innovators in cell and gene therapy. This two-day event will feature discussions on biopreservation, cryopreservation, and regulatory guidance, led by industry experts. Attendees will also have opportunities for networking and hands-on experiences.
Read more →BLFS▲ +5.1%on this news
BioLife Solutions Acquires PanTHERA CryoSolutions to Advance Leadership as a Pure Play Bioproduction Consumables Company
BioLife Solutions has acquired PanTHERA CryoSolutions, enhancing its offerings in biopreservation technologies. This strategic move is aimed at reinforcing BioLife's position in the cell and gene therapy market, with the addition of PanTHERA's Ice Recrystallization Inhibitor technology. The acquisition is part of BioLife's ongoing Bioproduction Innovation Accelerator initiative, which has successfully led to prior acquisitions. The deal includes a cash transaction along with shares and potential future payouts based on performance milestones.
Read more →BLFSOptimizing Biopreservation Strategies for Apheresis-Derived Cells in Immunotherapeutic Applications
The article discusses the importance of optimizing biopreservation strategies for apheresis-derived cells in immunotherapy. It highlights the challenges posed by variability in cell collection and processing, emphasizing the need for standardized protocols. Innovations in cryopreservation and specialized preservation solutions are presented as key advancements to improve cell stability and therapeutic efficacy. The article concludes with a call for collaboration to enhance the scalability of cell therapies.
Read more →BLFSBioLife Solutions Appoints Cathy Coste as Director and Audit Committee Chair
BioLife Solutions has appointed Cathy Coste to its board of directors, expanding the board to seven members. She will serve as the chair of the audit committee, succeeding Joydeep Goswami. Coste, a former senior partner at Deloitte with extensive experience in life sciences and risk management, expressed enthusiasm about joining BioLife at a time when the company is transitioning to a pure-play enabler of cell and gene therapies. Her background includes significant roles in corporate finance and governance, which are expected to benefit the company's strategic initiatives.
Read more →BLFSBioLife Solutions Reports Fourth Quarter and Full Year 2024 Financial Results
BioLife Solutions (BLFS) reported its financial results for the fourth quarter and full year 2024, highlighting a 12% year-over-year increase in Cell Processing revenue. The company achieved a GAAP gross margin of 60% for the fourth quarter, while adjusting EBITDA reached $4.0 million. BioLife introduced guidance for 2025, projecting total revenue growth of 16% to 20%. Despite a net loss from continuing operations of $2.0 million, the company expects its revenue trajectory to continue upward, driven by its optimized product portfolio and sales from non-core businesses.
Read more →BLFSBioLife Solutions to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on March 3, 2025
BioLife Solutions, Inc. has announced that it will report its fourth quarter and full year 2024 financial results on March 3, 2025. The company will also host a conference call and webcast to discuss these results and provide a business update starting at 8:00 AM ET. This event is part of their strategy to maintain transparency with investors and stakeholders in the bioproduction market.
Read more →BLFSHow to prepare early for regulatory submissions from IND to BLA
The article discusses the importance of early preparation for Investigational New Drug (IND) and Biologics License Application (BLA) submissions in the cell and gene therapy sector. It outlines the necessary documentation and steps involved in the IND process and emphasizes the role of the BLA in ensuring product safety and efficacy. BioLife Solutions offers guidance to drug manufacturers to streamline their submissions and navigate regulatory requirements effectively.
Read more →BLFSNavigating Current Standards and Compliance for Cell and Gene Therapy (CGT) Storage Containers
The article discusses the critical role of storage containers in the integrity and safety of Cell and Gene Therapy (CGT) products. It highlights the reliance on established pharmaceutical standards, such as those from the USP, to guide the selection and design of these containers. Key aspects include compliance with safety regulations, container closure integrity testing, and the need for rigorous inspection standards to ensure product viability. The article underscores the importance of addressing particulate risks and maintaining high standards for CGT storage solutions.
Read more →BLFSBioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2024 Unaudited Revenue from Continuing Operations
BioLife Solutions (NASDAQ: BLFS) announced its preliminary unaudited revenue for the fourth quarter and full year 2024, showcasing a 31% increase from the previous year, amounting to $22.7 million for Q4. Full year revenue rose to $82.3 million, exceeding prior guidance, driven primarily by the cell processing segment. CEO Roderick de Greef noted the significance of these results, emphasizing the company's focused strategy following recent business divestitures. BioLife, leveraging its biopreservation solutions, aims to capitalize on the evolving demand in the cell and gene therapy market.
Read more →BLFSBioLife Solutions Appoints Tony J. Hunt to its Board of Directors
BioLife Solutions has appointed Tony J. Hunt, Executive Chairman of Repligen Corporation, to its board of directors, effective January 2, 2025. Hunt, recognized for his leadership in bioprocessing innovation, will help advance BioLife's position in the cell and gene therapy market. His extensive experience includes previous roles that emphasized growth through acquisitions and product development. This appointment increases the board's membership to six and underscores BioLife's commitment to enhancing its bioproduction workflows.
Read more →BLFSCryoCase: Rethink the standard. Replace the bag.
BioLife Solutions has launched the CellSeal® CryoCase™, a rigid primary container for cell and gene therapy storage. This innovative product aims to replace traditional storage containers, offering benefits such as fracture resistance, transparency for easy inspection, and automation readiness. The CryoCase is designed to enhance efficiency and reduce contamination risks in CGT workflows.
Read more →BLFS▼ -10.2%on this news
BioLife Solutions Announces $6.1 million Sale of its Custom Biogenic Systems Freezer Subsidiary
BioLife Solutions (NASDAQ: BLFS) has announced the sale of its freezer subsidiary, Custom Biogenic Systems, for $6.1 million in cash. This move completes the company's strategic divestiture of its freezer and related businesses, following the earlier sale of Global Cooling. The decision reflects BioLife's aim to refocus on proprietary, higher-margin products in the cell processing market, aligning with their growth strategy in the cell and gene therapy sectors.
Read more →BLFSBioLife Solutions Announces $73 Million Sale of its SciSafe Biostorage Subsidiary
BioLife Solutions has announced the sale of its subsidiary SciSafe Holdings for $73 million, a strategic move aimed at refocusing on proprietary and higher-margin products. The sale is expected to enhance BioLife's balance sheet, which reported SciSafe generating $10.4 million in revenue for the first half of 2024. Additionally, the transaction leads to management changes within BioLife and the newly independent SciSafe. The CEO of BioLife indicated that this divestiture supports their ongoing mission and enriches shareholder value.
Read more →BLFSBioLife Solutions Reports Third Quarter 2024 Financial Results
BioLife Solutions, Inc. reported its financial results for Q3 2024, showcasing a 30% increase in total revenue compared to the previous year. The company also revised its revenue guidance for 2024 upwards for the Cell Processing platform, while adjusting total revenue expectations down due to the recent divestiture of its SciSafe biostorage business. Gross margins have improved, yet the company still recorded a net loss from continuing operations. The CEO expressed confidence in future growth opportunities driven by focused investment in high-margin products.
Read more →BLFSCustomer Applications of CryoStor® and HypoThermosol® FRS in Cell & Gene Therapy and Regenerative Medicine
CryoStor and HypoThermosol FRS are crucial biopreservation media in Cell and Gene Therapy and regenerative medicine, with over 700 clinical applications. These solutions are recognized for their versatility and effectiveness in preserving cells and tissues. Although not classified as drugs, they play a significant role in customer processes and therapeutic endeavors.
Read more →BLFSBioLife Solutions to Report Third Quarter 2024 Financial Results and Business Update on November 12, 2024
BioLife Solutions, Inc. has announced that it will report its financial results for the third quarter of 2024 on November 12, 2024. The report will be released after market close, followed by a conference call at 4:30 PM ET. During this call, management will discuss the financial results and provide updates on the business's performance. The event highlights BioLife's commitment to transparency and communication with its stakeholders.
Read more →BLFSWhat COVID Taught Us About the Benefits of Cryopreservation for Cell-Based Therapies
The COVID-19 pandemic highlighted the advantages of cryopreservation in cell and gene therapies, showcasing its role in ensuring the availability of donor cells despite logistical challenges. The demand for cryopreserved products has remained higher than pre-pandemic levels, indicating a shift in practices within the biotherapy sector. Cryopreservation is now viewed as a vital component in expanding patient access to treatments.
Read more →BLFSBioLife Solutions Expands Evidence Library With Citations of Bioproduction Tools in Scientific and Clinical Research
BioLife Solutions has expanded its Evidence Library, enhancing navigation and search capabilities for users seeking information on bioproduction and biopreservation tools. The library categorizes data related to various stages of cell and gene therapy research, allowing for easier access to relevant publications and performance data. The company emphasizes its commitment to continuously update the library with new evidence from scientific research.
Read more →BLFSBioLife Solutions Reports Second Quarter 2024 Financial Results
BioLife Solutions reported its financial results for the second quarter of 2024, highlighting an 11% sequential increase in Cell Processing revenue. The company raised its full-year revenue guidance to between $99.0 million and $101.0 million, reflecting a strong outlook amid favorable market conditions. Despite a net loss from continuing operations of $7.1 million, improvements in gross margins and adjusted EBITDA point to increasingly stable operations. The company continues to align strategically with the growing cell and gene therapy market, which is expected to drive future growth.
Read more →BLFSHow the BioLife Solutions Master File Letter Request Process Works for CryoStor® and HypoThermosol® FRS
BioLife Solutions offers Master Files for CryoStor and HypoThermosol FRS, which are essential in cell and gene therapy processes. These files facilitate customer submissions to the US FDA. The article details how customers can request a Master File Letter to cross-reference these files, ensuring a streamlined regulatory process. BioLife's support is highlighted for both US and international submissions.
Read more →BLFSHow Does a Water-Free Automated Thawing System Improve Your Cryopreservation Process?
The article discusses the importance of thawing in cryopreservation, emphasizing the need for standardized processes to enhance cell viability in critical therapies. It highlights the advancements in automated thawing systems, particularly the ThawSTAR technology, which ensures reproducible thawing results. The article also compares current thawing methods, advocating for automation to reduce variability and contamination risks.
Read more →BLFSBioLife Solutions to Report Second Quarter 2024 Financial Results and Business Update on August 8, 2024
BioLife Solutions, Inc. is scheduled to release its second quarter 2024 financial results on August 8, 2024, after market closure. The company will provide a comprehensive business update during a conference call at 4:30pm ET. Investors can access the call via the company's Investor Relations page or through a toll-free number. A replay of the webcast will be available shortly after the event.
Read more →BLFS▲ +8.6%on this news
Overcoming Cryopreservation Challenges
BioLife Solutions has collaborated with Cell and Gene Therapy Insights to address the challenges of cryopreservation in cell-based research. The partnership produced a poster outlining best practices to enhance cell viability during the cryopreservation process. Key strategies include using cryoprotectants, controlled-rate freezing, and automated thawing systems to ensure the integrity of biological materials.
Read more →BLFSBioLife Solutions Introduces the CellSeal CryoCase™ at International Society for Cell & Gene Therapies (ISCT) Conference in Vancouver
BioLife Solutions has unveiled the CellSeal CryoCase™ at the ISCT Conference in Vancouver, designed for primary packaging in cell and gene therapies. This innovative container replaces traditional cryopreservation bags with a more durable, rigid construction suitable for automated systems. The CryoCase allows for better protection of biological materials and has shown promising results in early testing, including improved viability and reduced particle contamination. The product is expected to be available for CGT developers starting in August 2024.
Read more →BLFSBioLife Solutions Reports First Quarter 2024 Financial Results
BioLife Solutions, Inc. reported its financial results for the first quarter of 2024, revealing a 10% sequential increase in core cell processing revenue. The company achieved an adjusted gross margin expansion from 40% to 53% after divesting its freezer business, which significantly improved its financial position. Despite a net loss of $10.2 million, BioLife affirmed its revenue guidance of $95.5 million to $100 million for the year, citing positive momentum in the cell and gene therapy market.
Read more →BLFSBioLife Solutions to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
BioLife Solutions, Inc. has announced that its financial results for the first quarter of 2024 will be released on May 9, 2024, after market close. A conference call and live webcast will take place at 4:30 PM ET to discuss the results and provide a business update. Stakeholders can access the webcast through the company's Investor Relations webpage. This release reflects BioLife's commitment to keeping investors informed about its performance and strategic direction.
Read more →BLFSBioLife Solutions Announces the Divestiture of its Stirling Freezer Business
BioLife Solutions has completed the sale of its subsidiary Global Cooling, Inc., known for its Stirling freezer business. The CEO announced that this divestiture would significantly reduce quarterly cash expenditures and eliminate substantial warranty liabilities. The company expects the transaction to positively impact its financial performance, leading to higher revenue growth and enhanced gross margins. Further financial details related to the deal will be filed with the SEC in a Current Report.
Read more →BLFSThe History of Cryopreservation
The article explores the evolution of cryopreservation, highlighting key breakthroughs from the 1948 discovery of freezing fowl spermatozoa to modern advancements like BioLife Solutions' CryoStor. It discusses the challenges faced in the field, particularly with home-brewed solutions, and emphasizes the importance of cGMP compliance and optimized formulations for effective cell preservation. The future of cryopreservation looks promising with ongoing innovations.
Read more →BLFSUniversal Cell Management System – What is it? and Why is it important to the Cell and Gene Therapy (CGT) Industry?
The article discusses the Universal Cell Management System (UCMS), specifically the Signata CT-5, which is designed to optimize cell and gene therapy manufacturing. It highlights the system's versatility in handling tasks such as final fill, media formulation, and bioreactor fill. The Signata CT-5 aims to improve efficiency while minimizing contamination risks in the production process.
Read more →BLFSBioLife Solutions to Present at TD Cowen and Key Bank Investor Conferences
BioLife Solutions, Inc. is set to present at March investor conferences including the TD Cowen Annual Healthcare Conference and the Key Banc Virtual Conference. CEO Roderick de Greef and CFO Troy Wichterman will participate in meetings and fireside chats aimed at current and prospective investors. This engagement is expected to bolster the company's visibility in the biopharma sector.
Read more →BLFSBioLife Solutions Reports Fourth Quarter and Full Year 2023 Financial Results
BioLife Solutions reported its financial results for Q4 and full year 2023, highlighting a sequential revenue increase in its Cell Processing segment. The company introduced its 2024 revenue guidance, projecting between $95.5 million and $100 million, excluding its freezer business, and expects positive adjusted EBITDA. However, total revenue for the year dropped 11%, influenced by the divestiture of lower-margin segments and a significant operating loss due to asset impairment. The company aims for higher-margin growth through its biopreservation media and services.
Read more →BLFSBioLife Solutions to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update on February 29, 2024
BioLife Solutions, Inc. (NASDAQ: BLFS) announced that it will report its fourth quarter and full year 2023 financial results on February 29, 2024. The company will host a conference call and live webcast to discuss these results and provide a business update. This event demonstrates the company's commitment to keeping investors informed about its performance and developments in the bioproduction industry.
Read more →BLFSEmpowering Your Downstream Cell and Gene Therapy Processes: A Sexton Biotechnologies Focus
BioLife Solutions has acquired Sexton Biotechnologies to enhance its capabilities in supporting cell and gene therapy (CGT) developers. The acquisition allows BioLife to offer advanced media, automated manufacturing equipment, and CGT storage solutions. The focus is on improving downstream processes and ensuring better clinical outcomes through innovative tools and expert guidance.
Read more →BLFSHow to Choose the Right Freeze Media
The article discusses the importance of selecting appropriate cryopreservation media for cell preservation, highlighting both home-brew and commercial options. It emphasizes the role of cryoprotectants in preventing ice crystal formation and ensuring cell viability. Notable products like CryoStor and HypoThermosol FRS are presented for their unique benefits. The article concludes that tailored media selection is essential for successful cryopreservation.
Read more →BLFS▲ +10.2%on this news
BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2023 Unaudited Revenue
BioLife Solutions, Inc. announced preliminary unaudited revenue for the fourth quarter and full year 2023. The firm reported an 11% sequential increase in core cell processing revenue to $14.8 million, although this represented a 26% drop compared to the same quarter in the previous year. The company is cautiously optimistic about macroeconomic conditions improving, with the divestiture of its freezer business expected to enhance its financial profile. Overall, revenue for the full year 2023 decreased by 11% from 2022.
Read more →BLFSBiopreservation Extends Shelf-Life and Eases Logistics for Starting Materials in CGT
The cell and gene therapy (CGT) industry is advancing but faces challenges in managing starting materials. Biopreservation techniques, such as hypothermic and cryopreservation media, can extend the shelf-life and improve the quality of these materials. Optimizing these processes is crucial for enhancing clinical success and manufacturing efficiency in CGT.
Read more →BLFS▲ +6.8%on this news
Biopreservation Best Practices For Your Cryopreservation Process May Optimize Your Post-Thaw Viable Recovery
BioLife Solutions emphasizes the importance of biopreservation best practices in cryopreservation processes to enhance post-thaw viable recovery of cell-based therapies. The article outlines key steps and considerations for optimizing cryopreservation, including the use of tailored solutions like CryoStor and controlled-rate freezing techniques. These practices aim to minimize cell damage and improve overall yield and functionality.
Read more →BLFSBioLife Solutions Reports Third Quarter 2023 Financial Results
BioLife Solutions reported its third quarter financial results for 2023, revealing a total revenue of $33.3 million, an 18% decline from the same period last year. The biostorage services platform showed notable growth of 50%, excluding COVID-related revenue, while overall revenue was affected by a decrease in the cell processing segment. The company is currently restructuring following leadership changes and is moving towards the divestiture of its freezer operations, expected to conclude in early 2024.
Read more →BLFS▲ +8%on this news
BioLife Solutions to Provide Third Quarter 2023 Financial Results and Business Update on November 9, 2023
BioLife Solutions, Inc. has announced that it will release its third quarter financial results on November 9, 2023, after the market closes. A conference call and live webcast will follow at 4:30 PM ET, allowing management to present the financial overview and a general business update. Access to the call will be available through their Investor Relations webpage and a toll-free number. A replay will also be provided post-call for further accessibility.
Read more →BLFSBioLife Solutions Announces Leadership Transitions & Preliminary Third Quarter Revenue with Updated Outlook for 2023
BioLife Solutions has appointed Roderick de Greef as Chairman and CEO, succeeding Michael Rice, who retired after 17 years. Concurrently, Garrie Richardson was appointed Chief Revenue Officer. The company reported preliminary Q3 revenue of approximately $33.3 million and expects 2023 revenue to be at the low end of prior guidance. De Greef aims to enhance focus on cell processing and biostorage, navigating a dynamic operating environment while managing inventory levels.
Read more →BLFSBioLife Solutions Reports Second Quarter 2023 Financial Results, Updates Full Year 2023 Guidance and Provides Pro Forma First Half 2023 Financial Profile Excluding Freezer Business
BioLife Solutions announced its second quarter 2023 financial results and updated its guidance, indicating a commitment to divest its Stirling Ultracold and Custom Biogenic Systems freezer assets by the end of the year. The company highlighted improved pro forma financial metrics excluding these assets, while also reporting a decrease in total revenue and challenges due to market conditions. Despite these short-term setbacks, management expressed confidence in long-term growth potential, citing new customer acquisitions and increased demand in the cell and gene therapy sector.
Read more →BLFSBioLife Solutions to Provide Second Quarter 2023 Financial Results and Business Update on August 8, 2023
BioLife Solutions, Inc. (NASDAQ: BLFS) announced that it will release its second quarter financial results on August 8, 2023. The company will hold a conference call and live webcast at 4:30 pm ET on the same day, where management will provide an overview of financial performance and a general business update. This event underscores the firm's commitment to transparency and communication with its investors.
Read more →BLFSBioLife Solutions Receives College of American Pathologists CAP-BAP Accreditation for All SciSafe® U.S. Biostorage Facilities
BioLife Solutions announced that all its SciSafe-branded biostorage facilities in the USA have received CAP-BAP accreditation from the College of American Pathologists. This prestigious accreditation demonstrates the company's commitment to providing high-quality biostorage services. The facilities meet stringent quality standards, which are considered equal to or more rigorous than federal inspection programs. With this achievement, BioLife enhances its reputation in the biopharma market as a trusted provider of bioproduction tools and services.
Read more →BLFSBioLife Solutions Launches the IntelliRate™ i67C Liquid Nitrogen (LN2) Controlled-Rate Freezer
BioLife Solutions has announced the launch of its IntelliRate i67C, a large-capacity controlled-rate freezer designed for cell and gene therapy production. This new tabletop freezer is 40% larger than its competitors, allowing for greater efficiency and scalability in clinical and commercial manufacturing processes. With advanced features such as a user-friendly touchscreen controller and extensive programming capabilities, the i67C aims to meet increasing demand in the biopharma market. The product is now available for order, further expanding BioLife's range of bioproduction tools.
Read more →BLFS▼ -5%on this news
BioLife Solutions to Provide First Quarter 2023 Financial Results and Business Update on May 10, 2023
BioLife Solutions, Inc. (NASDAQ: BLFS) will release its first quarter financial results on May 10, 2023. Following the release, the company will host a conference call and webcast to discuss the results and provide a business update. This engagement with investors highlights BioLife's commitment to transparency in the financial sector.
Read more →BLFS▼ -7%on this news
BioLife Solutions Reports Preliminary and Unaudited 2022 Fourth Quarter and Full Year Financial Results
BioLife Solutions reported its preliminary financial results for Q4 and full year 2022, showing a robust growth trajectory with record revenues. The company's full year revenue reached $161.8 million, representing a 36% increase from the previous year, while new customer acquisitions surpassed 1,300. Despite achieving positive adjusted EBITDA, the company reported an operating loss of $145.5 million due to significant impairment charges. Looking ahead, BioLife aims to capitalize on the anticipated growth in the cell and gene therapy sector through new approvals and increased market presence.
Read more →BLFS▼ -13.3%on this news
BioLife Solutions Reports Immaterial Financial Exposure to Silicon Valley Bank
BioLife Solutions has reported that its financial exposure to Silicon Valley Bank is immaterial, with less than $1 million held there, which does not constitute a significant part of its finances. The company does not perceive any risk to its operations in light of the current situation at SVB and maintains multiple custodians for third-party investments. BioLife continues to monitor the developments surrounding SVB and is assessing the implications of its credit facility.
Read more →BLFSBioLife Solutions to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 16, 2023
BioLife Solutions, Inc. announced that it will release its fourth quarter and full year 2022 financial results after market close on March 16, 2023. Following the release, the company will hold a conference call and live webcast to discuss the results and provide a business update. The event reflects BioLife's commitment to keeping investors informed about its performance and ongoing operations within the cell and gene therapy markets.
Read more →BLFSBioLife Solutions Launches Ultraguard™ -70°C Phase Change Material (PCM) Accessory to Provide Backup Cooling in ULT Freezers and Dry Ice Alternative for Benchtop Biologic Material Storage
BioLife Solutions, Inc. has launched Ultraguard, the first non-toxic and non-flammable phase change material (PCM) that operates at -70°C. This innovation provides backup cooling for ultra-low temperature freezers and serves as a dry ice alternative for biologic material storage. Ultraguard aims to mitigate risks associated with power outages and supply challenges in cold chain logistics. The product has been successfully beta tested with major health organizations and logistics providers, showcasing its potential impact in the life sciences sector.
Read more →BLFS▲ +6%on this news
BioLife Solutions Announces 2023 Analyst Day & Participation in Upcoming Investor Conferences
BioLife Solutions, Inc. has announced its 2023 Analyst Day set for March 23, 2023, at its SciSafe biorepository in Billerica, MA, where executives will provide updates on products and financial performance. The event aims to engage with both sell-side and buy-side analysts, as well as shareholders. Additionally, BioLife will be participating in multiple upcoming investor conferences, enhancing its visibility in the biopharma market.
Read more →BLFSBioLife Solutions Named One of Seattle Business Magazine
BioLife Solutions, Inc. has been recognized as one of Seattle Business magazine's Best Companies to Work for, marking the fourth time in nine years the company has achieved this honor. The recognition is based on both workplace policies and employee feedback, with the latter accounting for a significant portion of the evaluation. The company has seen considerable growth since 2013, increasing its workforce and expanding its reach beyond Washington state. This acknowledgment not only highlights BioLife's commitment to its employees but also its prominence within the biopharma sector.
Read more →BLFS▲ +9%on this news· ran to +26% by day 3shared move
BioLife Solutions Announces 2022 Fourth Quarter and Full Year Preliminary Unaudited Revenue and Introduces 2023 Revenue Guidance
BioLife Solutions reported record revenues for the fourth quarter and the full year of 2022, with quarterly revenue increasing by 19% to $44.4 million and annual revenue climbing 36% to $161.9 million. The company has introduced revenue guidance for 2023, projecting a range between $188 million to $202 million, which suggests further growth between 16% to 25% compared to the previous year. The Cell Processing Platform continued to show strong growth, contributing significantly to overall revenue gains. Management remains optimistic about enhancing growth and operational performance despite ongoing market challenges.
Read more →BLFSBioLife Solutions to Announce Preliminary 2022 Revenue and Introduce 2023 Revenue Guidance on January 9, 2023
Announcement Precedes Meetings to be Held During the J.P. Morgan Health Care Conference; Updated Investor Presentation Demonstrates Continued Execution to Drive High-Margin, Recurring Revenue BOTHELL, Wash., Dec. 19, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a
Read more →BLFSBioLife Solutions Expands Intellectual Property Estate
7 New Granted Patents; 43 Submitted Patent Applications Global Portfolio Now Totals 148 Issued and 114 Pending Patents BOTHELL, Wash., Nov. 21, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-de
Read more →BLFS▼ -6.3%on this newsshared move
BioLife Solutions Named in BioSpace Best Places to Work in Biopharma 2023 Report
Only 60 Companies Selected – Based on 2,000 Respondents BOTHELL, Wash., Nov. 17, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene
Read more →BLFS▼ -15%on this news
BioLife Solutions Reports Third Quarter 2022 Financial Results
Record revenue of $40.7 million increased 21% over Q3 2021; biopreservation media revenue growth of 50%, validating leading position as a critical cell and gene therapies tool supplier Cash flow from operations of $1.5 million and adjusted EBITDA of $1.4 million Tightens 2022 r
Read more →BLFSBioLife Solutions to Report Third Quarter 2022 Financial Results and Provide Business Update on November 9, 2022
BOTHELL, Wash., Nov. 2, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's third quarter 2022 finan
Read more →BLFSBioLife Solutions Announces COO to Retire and Join Board of Directors
Roderick de Greef retirement planned for January 2023 with appointment to BioLife Board of Directors Geraint Phillips to assume responsibilities in January 2023 as newly promoted Senior Vice President, Global Operations BOTHELL, Wash., Oct. 3, 2022 /PRNewswire/ -- BioLife Solut
Read more →BLFSBioLife Solutions Appoints Cell Therapy Executive Timothy L. Moore to its Board of Directors
Industry veteran brings extensive technical operations scale-up experience and extreme fluency in cell therapy tools and services selection process BOTHELL, Wash., Aug. 25, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading develo
Read more →BLFSBioLife Solutions Reports Second Quarter 2022 Financial Results and Updates Full Year 2022 Revenue Guidance
Record revenue of $40.5 million increased 30% over Q2 2021, with organic revenue growth of 44% and biopreservation media revenue growth of 46% Updating 2022 revenue guidance to $160 million to $166 million, reflecting year-over-year growth of 34% to 39% and higher organic growth
Read more →BLFSBioLife Solutions to Report Second Quarter 2022 Financial Results and Provide Business Update on August 9, 2022
BOTHELL, Wash., Aug. 2, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's second quarter 2022 fina
Read more →BLFSBioLife Solutions Deploys SciSafe
The new service will enable life sciences companies to seamlessly move hardware as well as biomaterials at the local level BOTHELL, Wash., June 9, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services f
Read more →BLFS▼ -10.8%on this news
BioLife Solutions Reports First Quarter 2022 Financial Results
Revenue of $36.2 million increased 115% over Q1 2021, with organic revenue growth of 45% and biopreservation media revenue growth of 53% Affirms 2022 revenue guidance of $159.5 million to $171.0 million, reflecting year-over-year growth of 34% to 44% and organic growth of 28% to
Read more →BLFS▼ -10.8%on this news
BioLife Solutions Executes Co-Marketing Agreement with Coriell Institute for Medical Research to Offer Biostorage, Biospecimen Processing and Custom Laboratory Services
BOTHELL, Wash. , May 9, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced that it has executed a co-marketing ag
Read more →BLFSBioLife Solutions to Report First Quarter 2022 Financial Results and Provide Business Update on May 9, 2022
BOTHELL, Wash., May 2, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's first quarter 2022 financ
Read more →BLFSBioLife Solutions, Inc. Announces Change of Auditor to Grant Thornton LLP
BOTHELL, Wash., April 7, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT) and the broader biopharma markets, today
Read more →BLFS▲ +7.3%on this news
BioLife Solutions Receives Nasdaq Notice of Noncompliance for Delayed 10-K Filing
BOTHELL, Wash., March 18, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT) and biopharma markets, announced today
Read more →BLFS▲ +6.7%on this newsshared move
BioLife Solutions Announces Additional Delay in Filing of Annual Report on Form 10-K
BOTHELL, Wash., March 17, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT) and the broader biopharma markets, anno
Read more →BLFSBioLife Solutions Secures Strategic Customer Wins and Plans 2022 Expansion in $400 Million Biostorage Services Market
BOTHELL, Wash., March 15, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today provided additional details on its growth expe
Read more →BLFSBioLife Solutions to Attend and Present at Upcoming Investor Conferences
BOTHELL, Wash., March 1, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT) and the broader biopharma markets, today
Read more →BLFSBioLife Solutions Reports Unaudited Fourth Quarter and Full Year 2021 Financial Results
BOTHELL, Wash., Feb. 28, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT) and the broader biopharma markets, today
Read more →BLFSBioLife Solutions to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on February 28, 2022
BOTHELL, Wash., Feb. 21, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's fourth quarter and full
Read more →BLFSBioLife Solutions Announces Preliminary 2021 Revenue of $119 Million, Up 148% Over 2020
BOTHELL, Wash., Jan. 10, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets, today announced preliminary revenue for the fourth quarte
Read more →BLFSBioLife Solutions Collaborates with Seattle Children
BOTHELL, Wash., Jan. 4, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy and broader biopharma markets, today announced an extended collaboration with Seattle Children'
Read more →BLFS▼ -5.1%on this news
UNICEF Selects Ultra-Low Temperature (ULT) Freezers from BioLife Solutions to Extend Thermal Stability of COVID-19 Vaccines
BOTHELL, Wash., Dec. 16, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced a partnership with UNICEF to extend t
Read more →BLFSBioLife Solutions Ranks 353 Among Fastest-Growing Companies in North America on the 2021 Deloitte Technology Fast 500™
BOTHELL, Wash., Nov. 17, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced it has ranked 353 in the 27th annual
Read more →BLFS▲ +5.6%on this newsshared move
BioLife Solutions Named to Inc. Magazine Inaugural List of Best-Led Companies
BOTHELL, Wash., Nov. 15, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies and the broader biopharma markets, today annou
Read more →BLFSBioLife Solutions Announces Third Quarter 2021 Financial Results
BOTHELL, Wash., Nov. 11, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced
Read more →BLFSBioLife Solutions Announces Executive Management Changes
BOTHELL, Wash., Nov. 4, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (the "Company") (Nasdaq: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced changes to its executi
Read more →BLFSBioLife Solutions to Report Third Quarter 2021 Financial Results and Provide Business Update on November 11, 2021
BOTHELL, Wash., Nov. 4, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's third quarter 2021 finan
Read more →BLFSBiolife Solutions Supports Biostorage Best Practices Through SciSafe
BOTHELL, Wash., Oct. 26, 2021 /PRNewswire/ -- Biolife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for cell and gene therapies ("CGT"), and its biological material storage brand SciSafe, a multi-facility provider of storage
Read more →BLFSBioLife Solutions Leverages Expanded Bioproduction Tools and Services Portfolio in Multipoint Engagement with Leading CAR T-Cell Developer
BOTHELL, Wash., Oct. 4, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced a broad engagement with a leadi
Read more →BLFSBioLife Solutions Appoints Joydeep Goswami, MBA, PhD to Board of Directors
BOTHELL, Wash., Sept. 20, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced
Read more →BLFS▼ -5.9%on this newsshared move
BioLife Solutions Announces CFO Retirement
BOTHELL, Wash., Sept. 15, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced
Read more →BLFSBioLife Solutions Files Form S-3 Registration Statement to Register Shares from Completed Acquisitions
BOTHELL, Wash., Sept. 1, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, announces that i
Read more →BLFSBioLife Solutions Closes Acquisition of Sexton Biotechnologies
BOTHELL, Wash., Sept. 1, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced
Read more →BLFS▲ +19.6%on this news
BioLife Solutions Joins S&P SmallCap 600 Index
BOTHELL, Wash., Aug. 25, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced
Read more →BLFSBioLife Solutions Announces Second Quarter 2021 Financial Results
BOTHELL, Wash., Aug. 12, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced
Read more →BLFSBioLife Solutions to Acquire Sexton Biotechnologies to Expand Cell and Gene Therapy Tools Portfolio
BOTHELL, Wash., Aug. 9, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced t
Read more →BLFSBioLife Solutions to Report Second Quarter 2021 Financial Results and Provide Business Update on August 12, 2021
BOTHELL, Wash., Aug. 5, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, to
Read more →BLFS▼ -5.4%on this news
BioLife Solutions Announces Changes to Board of Directors
BOTHELL, Wash., July 14, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced
Read more →BLFSBioLife Solutions Adopts New Brand Identity
BOTHELL, Wash., June 15, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced
Read more →BLFSBioLife Solutions Announces Promotion of Caitlin Rice to Global Vice President, Customer Service
BOTHELL, Wash., May 19, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced t
Read more →BLFSBioLife Solutions Announces First Quarter 2021 Financial Results
BOTHELL, Wash., May 13, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced f
Read more →BLFSBioLife Solutions to Report First Quarter 2021 Financial Results and Provide Business Update on May 13, 2021
BOTHELL, Wash., May 6, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, tod
Read more →BLFSBioLife Solutions Announces Closing of Stirling Ultracold Acquisition and Expanded Partnership with Leading Global Biopharma CDMO
BOTHELL, Wash., May 3, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, tod
Read more →BLFSBioLife Solutions Launches New High Capacity Controlled Rate Freezer Line with First Shipment to a Leading Cell Therapy Developer
BOTHELL, Wash., April 15, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced that it has launc
Read more →BLFSBioLife Solutions Appoints Two New Independent Board Directors
BOTHELL, Wash., April 6, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced that it has appoin
Read more →BLFSBioLife Solutions Announces Fourth Quarter and Full Year 2020 Financial Results
BOTHELL, Wash., March 22, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced financial results
Read more →BLFSBioLife Solutions to Acquire Stirling Ultracold in an All-Stock Merger
BOTHELL, Wash., March 22, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced the signing of a
Read more →BLFSBioLife Solutions to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Business Update on March 22, 2021
BOTHELL, Wash., March 10, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced that the Company'
Read more →BLFSBioLife Solutions Promotes Marcus Schulz to Chief Revenue Officer
BOTHELL, Wash., Feb. 16, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced the promotion of M
Read more →BLFSBioLife Solutions Promotes Sarah Aebersold, J.D. to Global Vice President, Human Resources
BOTHELL, Wash., Jan. 5, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced the promotion of Sa
Read more →BLFSBioLife Solutions & Casdin Capital Innovation Accelerator Announce New Investments in Cell & Gene Therapy Bioproduction Tools
BOTHELL, Wash., Dec. 1, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced two new co-investme
Read more →BLFSBioLife Solutions Ranked 403rd Fastest Growing Company in North America on Deloitte
BOTHELL, Wash., Nov. 19, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced it was ranked numb
Read more →BLFSBioLife Solutions Announces Third Quarter 2020 Financial Results
BOTHELL, Wash., Nov. 5, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced financial results f
Read more →BLFSBioLife Solutions to Report Third Quarter 2020 Financial Results and Provide Business Update on November 5, 2020
BOTHELL, Wash., Oct. 29, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced that the Company's
Read more →BLFSBioLife Solutions SciSafe Division Secures $2.7 Million Cold Chain and Storage Contract for COVID-19 Vaccines
BOTHELL, Wash., Oct. 14, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools and services for cell and gene therapies, today announced its recently acquired
Read more →BLFSBioLife Solutions Closes Acquisition of SciSafe, a High-Growth Biostorage Service Provider to the Cell and Gene Therapy Industry
BOTHELL, Wash., Oct. 1, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced it has closed the acquisition of Sc
Read more →BLFSBioLife Solutions to Acquire SciSafe, a High-Growth Biostorage Service Provider to the Cell and Gene Therapy Industry
BOTHELL, Wash., Sept. 21, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced it has entered into a definitive
Read more →BLFSBioLife Solutions Named one of the Top 100 Companies in Washington State
BOTHELL, Wash., Aug. 25, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, was recently named one of the 100 Best Companies t
Read more →BLFSBioLife Solutions Announces Second Quarter 2020 Financial Results
BOTHELL, Wash., Aug. 6, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced financial results for the three and
Read more →BLFSBioLife Solutions to Report Second Quarter 2020 Financial Results and Provide Business Update on August 6, 2020
BOTHELL, Wash., July 30, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced that the Company's second quarter
Read more →BLFSBioLife Solutions evo® Cold Chain Management Platform Now Supporting Over 100 Early Stage Cell & Gene Therapy Clinical Trials
BOTHELL, Wash., July 15, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today provided an update on adoption of its evo co
Read more →BLFSBioLife Solutions Announces Closing of $86 Million Public Offering of Common Stock
BOTHELL, Wash., July 7, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced the closing of its public offering
Read more →BLFSBioLife Solutions Announces Pricing of $75 Million Public Offering of Common Stock
BOTHELL, Wash., July 2, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced the pricing of its public offering
Read more →BLFSBioLife Solutions Announces $9.6 Million to $9.8 Million in Preliminary Revenue for Q2 2020
BOTHELL, Wash., July 1, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced estimated preliminary revenue for t
Read more →BLFSBioLife Solutions Announces Proposed Public Offering of Common Stock
BOTHELL, Wash., July 1, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced it intends to offer shares of its c
Read more →BLFSBioLife Solutions Promotes Marcus Schulz to Vice President, Global Sales
BOTHELL, Wash., May 18, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced the promotion of Marcus Schulz to th
Read more →BLFSBioLife Solutions Announces First Quarter 2020 Financial Results
BOTHELL, Wash., May 14, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced financial results for the three mon
Read more →BLFSBioLife Solutions to Report First Quarter 2020 Financial Results and Provide Business Update on May 14th, 2020
BOTHELL, Wash., May 11, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced that the Company's first quarter 202
Read more →BLFSBioLife Solutions Announces Preliminary First Quarter 2020 Revenue
BOTHELL, Wash., May 1, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced preliminary revenue for the first qua
Read more →BLFSBioLife Solutions Announces Fourth Quarter and Full Year 2019 Financial Results
BOTHELL, Wash., March 11, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today reported financial results and operational h
Read more →BLFSBioLife Solutions Awarded Three New Patents for Cell and Gene Therapy Bioproduction Tools
BOTHELL, Wash., March 2, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of best-in-class bioproduction tools for cell and gene therapies, today announced three new patents for bioproduction tools related to the 2019 acquisitions of A
Read more →BLFSBioLife Solutions Announces Earnings Call Date and Upcoming Investor and Scientific Conferences
BOTHELL, Wash., Feb, 12, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced the dates for several key events:
Read more →BLFSBioLife Solutions Announces Executive Appointments to Support Integration of Acquired Companies
BOTHELL, Wash., Dec. 2, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced several executive appointments to fu
Read more →BLFSBioLife Solutions Acquires Custom Biogenic Systems
BOTHELL, Wash., Nov. 12, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced the acquisition of substantially al
Read more →BLFSBioLife Solutions Announces Third Quarter 2019 Financial Results
BOTHELL, Wash., Nov. 12, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today reported financial results and operational hi
Read more →BLFSBioLife Solutions Named one of the Fastest Growing Companies in North America on Deloitte
BOTHELL, Wash., Nov. 7, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced that based on revenue growth from 2015 to 2018, it has been selec
Read more →BLFSBioLife Solutions to Report Third Quarter 2019 Financial Results and Provide Business Update on November 12, 2019
BOTHELL, Wash., Oct. 31, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of best-in-class bioproduction tools for cell and gene therapies, ("BioLife" or the "Company"), today announced that the Company's third quarter 2019 financial r
Read more →BLFSBioLife Solutions Awarded Three New Patents for Cryopreservation, Thawing and Cold Chain Transport Technologies
BOTHELL, Wash., Oct. 14, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of best-in-class bioproduction tools for cell and gene therapies, today announced three new patents for inventions related to cryopreservation, thawing and cold
Read more →BLFSBioLife Solutions Announces Cell and Gene Therapy Bioproduction Innovation Accelerator
BOTHELL, Wash., Sept. 24, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of best-in-class bioproduction tools for cell and gene therapies, today announced a co-investment accelerator program with Casdin Capital, targeting early stage
Read more →BLFSBioLife Solutions Announces New evo® Cold Chain Customers
BOTHELL, Wash., Sept. 16, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced several new customers have adopted the evo cold chain managemen
Read more →BLFSMustang Bio Adopts CryoStor® Freeze Media and evo® Cold Chain System for Cell and Gene Therapy Manufacturing and Distribution
BOTHELL, Wash., Sept. 3, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced that Mustang Bio, Inc. (NASDAQ: MBIO), a clinical-stage biopharm
Read more →BLFSBioLife Solutions Strengthens Sales Team with Key Leadership Additions
BOTHELL, Wash., Aug. 28, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced the hiring of two key sales executives who will assist in buildi
Read more →BLFSBioLife Solutions to Attend and Present at Upcoming Scientific and Investor Conferences
BOTHELL, Wash., Aug. 12, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that representatives of the Company
Read more →BLFSBioLife Solutions Completes Acquisition of SAVSU Technologies
BOTHELL, Wash., Aug. 8, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that it has executed a share exchange agreement to effect the acq
Read more →BLFSBioLife Solutions Announces Second Quarter 2019 Financial Results
BOTHELL, Wash., Aug. 8, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today reported financial results and operational hig
Read more →BLFSBioLife Solutions to Report Second Quarter 2019 Financial Results and Provide Business Update on August 8, 2019
BOTHELL, Wash., July 31, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media for cell and gene therapies, ("BioLife" or the "Company"), today announced that the Company's
Read more →BLFSSAVSU Technologies Expands IP Portfolio with Risk Mitigation Technologies for Shipping Cell and Gene Therapies
BOTHELL, Wash., July 30, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that SAVSU Technologies, a leading developer of advanced cold ch
Read more →BLFSSAVSU Technologies Partners with United Cargo® to Improve Cold Chain Management and Delivery of Cell and Gene Therapies
BOTHELL, Wash., July 23, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that SAVSU Technologies, a leading developer of advanced cold ch
Read more →BLFSBioLife Solutions to Acquire SAVSU Technologies
BOTHELL, Wash., July 8, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary biopreservation media and automated cell thawing media devices for cell and gene therapies, today announced that it has exercised i
Read more →BLFSBioLife Solutions to Join Russell 3000® Index
BOTHELL, Wash., June 10, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), the leading developer, manufacturer and marketer of proprietary biopreservation media and automated cell thawing devices for cell and gene therapies, today announced
Read more →BLFSBioLife Solutions to Present at the Jefferies 2019 Healthcare Conference
BOTHELL, Wash., May 30, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), the leading developer, manufacturer and marketer of proprietary biopreservation media and automated cell thawing devices for cell and gene therapies, today announced
Read more →BLFSBioLife Solutions Announces SAVSU Technologies Selected by Novartis to Supply Advanced Cold Chain Management Platform for Newly Approved Gene Therapy
BOTHELL, Wash., May 29, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), the leading developer, manufacturer and marketer of proprietary biopreservation media and automated cell thawing devices for cell and gene therapies, today announced
Read more →BLFSBioLife Solutions Announces First Quarter 2019 Financial Results
BOTHELL, Wash., May 9, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), the leading developer, manufacturer and marketer of proprietary biopreservation media and automated cell thawing media devices for cell and gene therapies, today repor
Read more →BLFSBioLife Solutions to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019
BOTHELL, Wash., May 2, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media for cell and gene therapies, ("BioLife" or the "Company"), today announced that the Company's f
Read more →BLFSBioLife Solutions Completes Acquisition of Astero Bio
BOTHELL, Wash., April 2, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife") today announced that it has closed the previously announced transaction for the acquisition of Astero Bio Corporation ("Astero"), an innovator in the design, development and commercia
Read more →BLFSBioLife Solutions Announces Fourth Quarter and Full Year 2018 Financial Results
BOTHELL, Wash., March 14, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary cell and tissue hypothermic storage and cryopreservation freeze media, today reported financial results and operation
Read more →BLFSBioLife Solutions Expands Cell and Gene Therapy Tools Portfolio with Acquisition of Astero Bio
BOTHELL, Wash., March 14, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife") today announced that it has entered into an agreement to acquire Astero Bio Corporation ("Astero"), a privately-held innovator in the design, development and commercialization of nov
Read more →BLFSBioLife Solutions to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Business Update on March 14, 2019
BOTHELL, Wash., March 4, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media for cell and gene therapies, ("BioLife" or the "Company"), today announced that the Company's
Read more →BLFSBioLife Solutions to Attend and Present at Upcoming Investor and Scientific Conferences
BOTHELL, Wash., Feb. 19, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary biopreservation media products for cell and gene therapies, today announced that management and scientific personnel w
Read more →BLFSNew Policies to Advance Development of Cell and Gene Therapies Announced by FDA
BOTHELL, Wash., Jan. 22, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary biopreservation media products for cell and gene therapies, expects to benefit from new policies to advance the development of saf
Read more →BLFSBioLife Solutions Completes Redemption of Series A Preferred Stock
BOTHELL, Wash., Nov. 27, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary biopreservation media products for cell and gene therapies, ("BioLife" or the "Company"), today announced it will redeem the remai
Read more →BLFSBioLife Solutions Announces Third Quarter 2018 Financial Results
BOTHELL, Wash., Nov. 8, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary biopreservation media products for cell and gene therapies, today reported financial results and operational highlights
Read more →BLFSBioLife Solutions to Report Third Quarter 2018 Financial Results and Provide Business Update on November 8, 2018
BOTHELL, Wash., Nov. 1, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media, ("BioLife" or the "Company"), today announced that the Company's third quarter 2018 financial
Read more →BLFSBioLife Solutions Reports Record Third Quarter 2018 Preliminary Revenue of $5.3 Million, up 79% Year-over-Year
BOTHELL, Wash., Oct. 1, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, today reported preliminary revenu
Read more →BLFSBioLife Solutions Increases Ownership in SAVSU Technologies to 44% with $5 Million Investment
BOTHELL, Wash., Sept. 5, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading supplier of proprietary biopreservation media products for cell and gene therapies, today announced that it has increased its ownership of SAVSU Technologies from approxi
Read more →BLFSBioLife Solutions to Ring NASDAQ Closing Bell on August 29, 2018
BOTHELL, Wash., Aug. 22, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading supplier of proprietary biopreservation media products for cell and gene therapies, today announced that CEO Mike Rice, accompanied by the senior management team and boar
Read more →BLFSBioLife Solutions Announces Second Quarter 2018 Financial Results
BOTHELL, Wash., Aug. 9, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, today reported financial results
Read more →BLFSCasdin Capital Invests $20 Million in BioLife Solutions to Support Strategic Growth Opportunities
BioLife Solutions, Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) (PRNewsfoto/BioLife Solutions, Inc.) BOTHELL, Wash., Aug. 9, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservat
Read more →BLFSBioLife Solutions to Present and Exhibit at Fall Investor and Cell & Gene Therapy Conferences
BOTHELL, Wash., Aug. 6, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media, ("BioLife" or the "Company"), today announced that representatives will be presenting and exh
Read more →BLFSBioLife Solutions to Report Second Quarter 2018 Financial Results and Provide Business Update on August 9, 2018
BioLife Solutions, Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) (PRNewsfoto/BioLife Solutions, Inc.) BOTHELL, Wash., Aug. 2, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservat
Read more →BLFSSandler Capital Funds to Increase Shareholding in BioLife Solutions
BioLife Solutions, Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) (PRNewsfoto/BioLife Solutions, Inc.) BOTHELL, Wash., July 9, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservat
Read more →BLFSBioLife Solutions Reports Second Quarter 2018 Preliminary Revenue of $5.2 Million, up 103% Year-over-Year and 36% Sequentially
BioLife Solutions, Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) (PRNewsfoto/BioLife Solutions, Inc.) BOTHELL, Wash., July 2, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade
Read more →BLFSBioLife Solutions to Join Russell Microcap® Index
BioLife Solutions, Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) (PRNewsfoto/BioLife Solutions, Inc.) BOTHELL, Wash., June 11, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical-grade biopreserva
Read more →BLFSBioLife Solutions to Present at the 2018 BIO International Convention
BioLife Solutions, Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) (PRNewsfoto/BioLife Solutions, Inc.) BOTHELL, Wash., May 29, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical-grade biopreservat
Read more →BLFSBioLife Solutions Announces Partial Redemption of Series A Preferred Stock
BioLife Solutions, Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) (PRNewsfoto/BioLife Solutions, Inc.) BOTHELL, Wash., May 17, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical-grade biopreservat
Read more →BLFSBioLife Solutions Makes Investment in SAVSU Technologies to Support Growth and Capture Additional Regenerative Medicine Cold Chain Opportunities
BioLife Solutions, Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) (PRNewsfoto/BioLife Solutions, Inc.) BOTHELL, Wash., May 16, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical-grade biopreservat
Read more →BLFSBioLife Solutions Announces First Quarter 2018 Financial Results
BioLife Solutions, Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) (PRNewsfoto/BioLife Solutions, Inc.) BOTHELL, Wash., May 10, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade
Read more →BLFSBioLife Solutions to Report First Quarter 2018 Financial Results and Provide Business Update on May 10, 2018
BioLife Solutions, Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) (PRNewsfoto/BioLife Solutions, Inc.) BOTHELL, Wash., May 3, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade hypothermic s
Read more →BLFSBioLife Solutions Receives $2.6 Million from Exercise of Warrants
BioLife Solutions, Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) (PRNewsfoto/BioLife Solutions, Inc.) BOTHELL, Wash., April 30, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and t
Read more →BLFSBioLife Solutions Announces Preliminary First Quarter 2018 Revenue of $3.8 Million, up 61% Year-over-Year and 22% Sequentially
BioLife Solutions, Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) (PRNewsfoto/BioLife Solutions, Inc.) BOTHELL, Wash., April 2, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade
Read more →BLFSBioLife Solutions and SAVSU Technologies to be Awarded Second Patent for Next Generation Cold Chain Technologies Designed for Cell and Gene Therapies
BOTHELL, Wash. and ALBUQUERQUE, N.M., March 26, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, and SAVSU Technologie
Read more →BLFSBioLife Solutions CryoStor® Cell Freeze Media Highlighted in Mayo Clinic/MD Anderson Journal Article on Preservation of Patient-Derived Xenografts for Cancer Research
BioLife Solutions, Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) (PRNewsfoto/BioLife Solutions, Inc.) BOTHELL, Wash., March 13, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grad
Read more →BLFSBioLife Solutions Announces Fourth Quarter and Full Year 2017 Financial Results
BioLife Solutions, Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) (PRNewsfoto/BioLife Solutions, Inc.) BOTHELL, Wash., March 8, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade
Read more →BLFSBioLife Solutions to Report Fourth Quarter and Full Year 2017 Financial Results and Provide Business Update on March 8, 2018
BioLife Solutions, Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) (PRNewsfoto/BioLife Solutions, Inc.) BOTHELL, Wash., March 1, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade hypothermic
Read more →BLFSBioLife Solutions Executes OEM Agreement with MilliporeSigma
BioLife Solutions, Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) BOTHELL, Wash., Feb. 13, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media ("BioLife" or the "Company
Read more →BLFSSAVSU Technologies and BioLife Solutions Increase evo® Intellectual Property Estate with Notice of Allowance of New Patent for Cold Chain Technologies
BioLife Solutions, Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) BOTHELL, Wash. and ALBUQUERQUE, N.M., Jan. 18, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermi
Read more →BLFSBioLife Solutions Announces Preliminary 2017 Revenue Increase of 34% to $11 Million
BioLife Solutions, Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) BOTHELL, Wash., Jan. 4, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical-grade cell and tissue hypothermic storage a
Read more →BLFSBioLife Solutions Executes Supply Agreement with Iovance Biotherapeutics
BioLife Solutions, Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) BOTHELL, Wash., Dec. 13, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media ("BioLife" or the "Company
Read more →BLFSBioLife Solutions Executes Additional Long-Term Supply Agreement with Leading T Cell Therapy Customer
BioLife Solutions, Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) BOTHELL, Wash., Nov. 29, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage
Read more →BLFSBioLife Solutions Announces Third Quarter 2017 Financial Results
Biolife Solutions Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) BOTHELL, Wash., Nov. 9, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage an
Read more →BLFSBioLife Solutions to Report Third Quarter 2017 Financial Results and Provide Business Update on November 9, 2017
Biolife Solutions Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) BOTHELL, Wash., Nov. 2, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze medi
Read more →BLFSBioLife Solutions and SAVSU Providing Enhanced Cold Chain Technologies for 8 UCSF Clinical Trials of Treg Cell Therapies
Biolife Solutions Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) BOTHELL, Wash. and ALBUQUERQUE, N.M., Oct. 31, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic
Read more →BLFSBioLife Solutions Receives $1.9 Million from Exercise of Warrants
BioLife Solutions, Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) BOTHELL, Wash., Oct. 30, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopres
Read more →BLFSBioLife Solutions Customer Kite Pharma Receives FDA Approval for Yescarta™ (Axicabtagene Ciloleucel) CAR T-Cell Therapy
Biolife Solutions Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) BOTHELL, Wash., Oct. 19, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryoprese
Read more →BLFSBioLife Solutions to Present at Upcoming Investor Conferences
Biolife Solutions Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) BOTHELL, Wash., Oct. 18, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryoprese
Read more →BLFSBioLife Solutions CryoStor® Cell Freeze Media Embedded in Cellular Biomedicine Group Clinical Trial of AlloJoin™
Biolife Solutions Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) BOTHELL, Wash., Sept. 19, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopres
Read more →BLFSBioLife Solutions to Present at September Investment Conferences
BioLife Solutions, Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) BOTHELL, Wash., Sept. 7, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopres
Read more →BLFSBioLife Solutions Announces Second Quarter 2017 Financial Results
Biolife Solutions Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) BOTHELL, Wash., Aug. 10, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryoprese
Read more →BLFSBioLife Solutions to Report Second Quarter 2017 Financial Results and Provide Business Update on August 10, 2017
BioLife Solutions, Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) BOTHELL, Wash., Aug. 3, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze med
Read more →BLFSBioLife Solutions Executes Supply Agreement with Celyad for CryoStor® Use in Natural Killer Receptor based T-Cell (NKR-T) Platform Targeting Solid Tumors and Blood Cancers
Biolife Solutions Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) BOTHELL, Wash., July 31, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryoprese
Read more →BLFSBioLife Solutions CryoStor® Cell Freeze Media Embedded in Invossa™: First Approved Cell and Gene Therapy for Osteoarthritis
Biolife Solutions Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) BOTHELL, Wash., July 13, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading supplier of pre-formulated, clinical grade cell and tissue hypothermic storage and cryopreservation freeze media ("B
Read more →BLFSBioLife Solutions Modifies Existing Credit Facility
Biolife Solutions Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) BOTHELL, Wash., July 5, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreserva
Read more →BLFSBioLife Solutions Executes Supply Agreement with Adaptimmune for CryoStor® Use in SPEAR T-Cell Platform
Biolife Solutions Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) BOTHELL, Wash., June 14, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreserv
Read more →BLFSBioLife Solutions Announces Q1 2017 Financial Results
Biolife Solutions Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) BOTHELL, Wash., May 11, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreserva
Read more →BLFSBioLife Solutions to Report First Quarter 2017 Financial Results and Provide Business Update on May 11, 2017
Biolife Solutions Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) BOTHELL, Wash., May 4, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media
Read more →BLFSBioLife Solutions Reports 4th Quarter and Full Year 2016 Results
BOTHELL, Wash., March 9, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media ("BioLife" or the "Company"), today reported op
Read more →BLFSBioLife Solutions to Report Fourth Quarter and Full Year 2016 Financial Results and Provide Business Update on March 9, 2017
BioLife Solutions, Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) (PRNewsfoto/BioLife Solutions, Inc.) BOTHELL, Wash., March 2, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tiss
Read more →BLFSBioLife Solutions Announces 2016 Revenue Growth of 28%
BioLife Solutions, Inc. logo. (PRNewsFoto/BIOLIFE SOLUTIONS INC.) (PRNewsfoto/BioLife Solutions, Inc.) BOTHELL, Wash., Jan. 12, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tiss
Read more →BLFSBioLife Solutions Amends Existing Credit Facility
BOTHELL, Wash., Jan. 10, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media ("BioLife"), today announced that it has reache
Read more →BLFSBioLife Solutions Restructures biologistex™ Joint Venture
BOTHELL, Wash., Jan. 3, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold cha
Read more →BLFSBioLife Solutions Executes 10 Year Supply Agreement with TissueGene for CryoStor® Use in Invossa™ Osteoarthritis Cell-Mediated Gene Therapy
BOTHELL, Wash., Dec. 20, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold ch
Read more →BLFSBioLife Solutions Reports Record Results for Third Quarter 2016
BOTHELL, Wash., Nov. 10, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold ch
Read more →BLFSBioLife Solutions to Report Third Quarter 2016 Financial Results and Provide Business Update on November 10, 2016
BOTHELL, Wash., Nov. 3, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("
Read more →BLFSBioLife Solutions and Brooks Life Sciences Partner on Study of Best Practices for Shipping and Storing Time and Temperature Sensitive Biologic Materials
BOTHELL, Wash., Oct. 26, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold ch
Read more →BLFSBioLife Solutions
BOTHELL, Wash., Sept. 15, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold c
Read more →BLFSBioLife Solutions Reports Results for Second Quarter 2016
BOTHELL, Wash., Aug. 11, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold ch
Read more →BLFSBioLife Solutions Executes 10 Year Supply Agreement with Bellicum Pharmaceuticals for CryoStor® Use in Cellular Immunotherapies
BOTHELL, Wash., Aug. 10, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold ch
Read more →BLFSBioLife Solutions to Report Second Quarter 2016 Financial Results and Provide Business Update on August 11, 2016
BOTHELL, Wash., Aug. 3, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("
Read more →BLFSBioLife Solutions Products Embedded in Cook MyoSite® Phase 3 Cell Therapy Clinical Trial for Stress Urinary Incontinence
BOTHELL, Wash., July 18, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold ch
Read more →BLFSBioLife Solutions Executes 10 Year Supply Agreement with Kite Pharma for CryoStor® Use in CAR T Cell Therapies
BOTHELL, Wash., July 11, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold ch
Read more →BLFSBioLife Solutions and MNX Global Logistics Partner to Support ImmunoCellular Therapeutics with Cold Chain Logistics in ICT-107 Phase 3 Clinical Trial in Glioblastoma
BOTHELL, Wash. and IRVINE, Calif., May 19, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted bi
Read more →BLFSBioLife Solutions Appoints Jim Mathers as New Vice President of Sales
BOTHELL, Wash., May 18, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold cha
Read more →BLFSBioLife Solutions Reports First Quarter 2016 Results
BOTHELL, Wash., May 12, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold cha
Read more →BLFSBioLife Solutions to Report First Quarter 2016 Financial Results and Provide Business Update on May 12, 2016
BOTHELL, Wash., May 6, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("B
Read more →BLFSBioLife Solutions Names Roderick de Greef Chief Financial Officer & Secretary
BOTHELL, Wash., May 4, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain manage
Read more →BLFSSeattle Business Magazine Names BioLife Solutions Washington State Manufacturer of the Year
BOTHELL, Wash., May 2, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chai
Read more →BLFSBiologistex LLC and MNX Global Logistics Partner to Offer Enhanced Cold Chain Logistics Services for Time and Temperature Sensitive Biologics, Vaccines & Cell Therapies
BOTHELL, Wash. and IRVINE, Calif., April 26, 2016 /PRNewswire/ -- Biologistex CCM, LLC, a joint venture of BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation
Read more →BLFSBioLife Solutions Names Cord Blood Industry Veteran Karen Foster Vice President of Operations
BOTHELL, Wash., April 4, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain mana
Read more →BLFSBioLife Solutions Provides Update on Customer Cell Therapy Clinical Trials and Development Programs
BOTHELL, Wash., March 14, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain man
Read more →BLFSBioLife Solutions to Present at 28th Annual ROTH Conference and 4th Annual ARM Cell & Gene Therapy Investor Day
BOTHELL, Wash., March 9, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain mana
Read more →BLFSBioLife Solutions Names Roderick de Greef Interim Chief Financial Officer
BOTHELL, Wash., March 7, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain mana
Read more →BLFSBioLife Solutions Reports 4th Quarter and Full Year 2015 Results
BOTHELL, Wash., Feb. 25, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold
Read more →BLFSBioLife Solutions to Report Fourth Quarter 2015 Financial Results and Provide Business Update on February 25, 2016
BOTHELL, Wash., Feb. 22, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues (
Read more →BLFSBioLife Solutions to Present at 18th Annual BIO CEO & Investors Conference
BOTHELL, Wash., Jan. 27, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold
Read more →BLFSNew Journal Articles Cite Expanded Use of BioLife Solutions Products in Clinical Cell Therapy Applications
BOTHELL, Wash., Jan. 25, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold
Read more →BLFSBioLife Solutions Announces 2015 Biopreservation Media Revenue Growth of 30%
BOTHELL, Wash., Jan. 7, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold c
Read more →BLFSBioLife Solutions Distributor STEMCELL Technologies Will Test the evo™ Smart Shipper and Cloud Based biologistex™ Cold Chain Management App
BOTHELL, Wash., Jan. 6, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold c
Read more →BLFSBioLife Solutions Customer Capricor Therapeutics Provides Update on Heart Failure Cell Therapy Safety Data at American Heart Association Scientific Sessions
BOTHELL, Wash., Nov. 23, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold
Read more →BLFSBioLife Solutions Makes Deloitte 2015 Technology Fast 500™
BOTHELL, Wash., Nov. 16, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold
Read more →BLFSBioLife Solutions Reports 3rd Quarter 2015 Results
BOTHELL, Wash., Nov. 12, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold
Read more →BLFSBioLife Solutions to Report Third Quarter 2015 Financial Results and Provide Business Update on November 12, 2015
BOTHELL, Wash., Nov. 2, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("
Read more →BLFSStem Cell Company CardioCell Utilizes BioLife Solutions CryoStor® in Phase II Clinical Trial for Heart Failure
BOTHELL, Wash., Oct. 22, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold
Read more →BLFSKiadis Pharma Utilizes BioLife Solutions HypoThermosol® to Improve Viability and Shelf Life of Donor Leukocytes in Clinical Trial of ATIR101™ T Cell Therapy for Blood Cancers
BOTHELL, Wash., Oct. 19, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold
Read more →BLFSBioLife Solutions Reports Record Revenue and Provides Operations Update for Q3 2015
BOTHELL, Wash., Oct. 5, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold c
Read more →BLFSBioLife Solutions Announces HemaCare Will Validate the evo™ Smart Shipper and Cloud Based biologistex™ Cold Chain Management App
BOTHELL, Wash., Sept. 17, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold
Read more →BLFSBioLife Solutions CryoStor® Commercial Grade Freeze Media Embedded in TC Biopharm ImmuniCell® Clinical Trial for Various Cancers
BOTHELL, Wash., Sept. 14, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold
Read more →BLFSBioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint
BOTHELL, Wash., Aug. 31, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold
Read more →BLFSBioLife Solutions to Report Second Quarter 2015 Financial Results and Provide Business Update on August 6, 2015
BOTHELL, Wash., July 29, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues (
Read more →BLFSBioLife Solutions Readies New BloodStor® 27 NaCl Cryopreservation Media to Support Customer Clinical Use of Frozen Platelets
BOTHELL, Wash., July 15, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and related cloud hosted biologistics cold chai
Read more →BLFSBioLife Solutions Announces Q2 2015 Revenue of $1.5 million with 33% Growth in Proprietary Products Revenue
BOTHELL, Wash., July 13, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and related cloud hosted biologistics cold chai
Read more →BLFSBioLife Solutions Named One of the 100 Best Companies to Work For in Washington State
BOTHELL, Wash., July 2, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold cha
Read more →BLFSSAVSU Technologies evo™ Smart Shipping Container, Marketed by BioLife Solutions, Wins 2015 Medical Design Excellence Award
SANTA FE, N.M. and BOTHELL, Wash., June 18, 2015 /PRNewswire/ -- SAVSU Technologies, a leading designer and manufacturer of innovative high performance passive storage and transport containers for temperature sensitive biologics and pharmaceuticals, and BioLife Solutions, Inc. (N
Read more →BLFSBioLife Solutions CryoStor® Cited in New Journal Article on Results of Phase I/II Clinical Trial of Dendritic Cell Immunotherapy for Prostate Cancer
BOTHELL, Wash., June 15, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold ch
Read more →BLFSBioLife Solutions Reports Increased Adoption of CryoStor® and HypoThermosol® Clinical Grade Biopreservation Media Products and Strong Interest in Cloud Based biologistex™ App & evo™ Smart Shipper at ISCT Conference
BOTHELL, Wash., June 3, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold cha
Read more →BLFSBioLife Solutions to Sponsor, Present, and Exhibit at the 2015 ISCT Conference: May 27 - 30 in Las Vegas
BOTHELL, Wash., May 26, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("
Read more →BLFSBioLife Solutions To Present At The 2015 Marcum MicroCap Conference In New York City
BOTHELL, Wash., May 22, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("B
Read more →BLFSBioLife Solutions to Report First Quarter 2015 Financial Results and Provide Business Update on May 7, 2015
BOTHELL, Wash., April 29, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues
Read more →BLFSCord Blood Registry® Uses BioLife Solutions CryoStor® Clinical Grade Freeze Media in the Storage of Umbilical Cord Tissue Stem Cells
BOTHELL, Wash., April 15, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues
Read more →BLFSBioLife Solutions Announces Preliminary Q1 2015 Revenue of $1.5 Million and Continued Product Adoption in the High Growth Regenerative Medicine Market
BOTHELL, Wash., April 13, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues
Read more →BLFSBioLife Solutions CryoStor® Cell Preservation Media Embedded in Cardio3 BioSciences
BOTHELL, Wash., April 9, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues (
Read more →BLFSBioLife Solutions Announces Fourth Quarter and Full Year 2014 Financial Results
BOTHELL, Wash., March 12, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues
Read more →BLFSBioLife Solutions to Report Fourth Quarter and Full Year 2014 Financial Results and Provide Business Update on March 12, 2015
BOTHELL, Wash., March 6, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues (
Read more →BLFSBioLife Solutions CryoStor® Cell Freeze Media Used in Mayo Clinic Safety and Feasibility Study of Umbilical Cord Blood-Derived Cells for Pediatric Cardiac Regeneration
BOTHELL, Wash., March 3, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues (
Read more →BLFSBioLife Solutions Wins Washington State 2015 Silver Award for Achievement in Medical Technology from Seattle Business Magazine
BOTHELL, Wash., March 2, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues (
Read more →BLFSBioLife Solutions Launches New Cell Thawing Media Products in Response to Worldwide Shortage of Dextran Solutions
BOTHELL, Wash., Feb. 11, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues (
Read more →BLFSBioLife Solutions Reports Preliminary Revenue for 2014
BOTHELL, Wash., Jan. 12, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues (
Read more →BLFSBioLife Solutions Biopreservation Media Products Embedded in 175 Cellular Immunotherapy & Other Regenerative Medicine Clinical Trials
BOTHELL, Wash., Jan. 5, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("
Read more →BLFSBioLife Solutions Sets Date for Annual Meeting of Stockholders
BOTHELL, Wash., Dec. 24, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues (
Read more →BLFSBioLife Solutions Names Pharmaceutical Industry Expert Kevin O
BOTHELL, Wash., Dec. 23, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues (
Read more →BLFSBioLife Solutions to Present at the LD Micro "Main Event" Investor Conference on Wednesday, December 3, 2014
BOTHELL, Wash., Nov. 25, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("
Read more →BLFSBioLife Solutions Launches Two New Product Packaging Options for BloodStor® and CryoStor® Freeze Media
BOTHELL, Wash., Nov. 17, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues (
Read more →BLFSBioLife Solutions Named to Deloitte
BOTHELL, Wash., Nov. 13, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues (
Read more →BLFSBioLife Solutions Announces Third Quarter 2014 Results
BOTHELL, Wash., Nov. 6, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("
Read more →BLFSBioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014
BOTHELL, Wash., Oct. 30, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues,
Read more →BLFSRoosterBio Selects BioLife Solutions CryoStor® to Commercialize Human Bone Marrow-Derived Stem Cells
BOTHELL, Wash., Oct. 21, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues (
Read more →BLFSBioLife Solutions Biopreservation Media Products Used at NeoStem Subsidiary Progenitor Cell Therapy
BOTHELL, Wash., Oct. 14, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues (
Read more →BLFSBioLife Solutions Announces Preliminary Revenue for Q3 2014 of $1.2 Million
BOTHELL, Wash., Oct. 6, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("
Read more →BLFSBioLife Solutions Forms biologistex CCM(SM) Joint Venture with SAVSU® Technologies to Market Intelligent, Controlled Temperature Containers for Biologics
BOTHELL, Wash., Sept. 30, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues
Read more →BLFSBioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board
BOTHELL, Wash., Sept. 23, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues
Read more →BLFSBioLife Solutions To Present At The 16th Annual Rodman & Renshaw Global Investment Conference In New York City And The Aegis Healthcare & Technology Conference In Las Vegas
BOTHELL, Wash., Sept. 8, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("
Read more →BLFSBioLife Solutions CryoStor® AND HypoThermosol® Now Embedded In 130 Regenerative Medicine Clinical Trials
BOTHELL, Wash., Aug. 25, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("
Read more →BLFSBioLife Solutions Announces Second Quarter 2014 Results
BOTHELL, Wash., Aug. 7, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("
Read more →BLFSBioLife Solutions CryoStor® Demonstrates Superior Cell Preservation In Multicenter Biobanking Study
BOTHELL, Wash., Aug. 4, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("
Read more →BLFSBioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014
BOTHELL, Wash., July 31, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues,
Read more →BLFSBioLife Solutions Announces Manufacturing Agreement With Somahlution LLC
BOTHELL, Wash., July 17, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues (
Read more →BLFSBioLife Solutions CryoStor® Freeze Media Adopted by TxCell for Ovasave® Regulatory T Cell-Based Personalized Immunotherapy
BOTHELL, Wash., June 16, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues t
Read more →BLFSFrost & Sullivan Selects BioLife Solutions Cell and Tissue Biopreservation Media for Technology Innovation Leadership Award
BOTHELL, Wash., June 11, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues (
Read more →BLFSBioLife Solutions to Present at LD Micro Conference
BOTHELL, Wash., May 19, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("
Read more →BLFSBioLife Solutions to Present at Third Annual Marcum MicroCap Conference
BOTHELL, Wash., May 12, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("
Read more →BLFSBioLife Solutions Announces First Quarter 2014 Results and Provides Business Update
BOTHELL, Wash., May 8, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("B
Read more →BLFSBioLife Solutions Stock Added to the Wilshire 5000(SM)
BOTHELL, Wash., April 21, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues,
Read more →BLFSBioLife Solutions Announces Preliminary Q1 2014 Revenue of $2 Million
BOTHELL, Wash., April 16, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues,
Read more →BLFSAdaptimmune Integrates BioLife Solutions CryoStor® Cell Freeze Media in Cancer Immunotherapy Clinical Trial
BOTHELL, Wash., April 2, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues,
Read more →BLFSBioLife Solutions Closes $15.4 Million Public Offering and Converts $14.3 Million of Debt to Equity
BOTHELL, Wash., March 25, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFS) today announced that is has closed a public offering of units for gross proceeds of approximately $15.4 million at a price of $4.30 per unit, completed the conversion of $14.3 million of debt int
Read more →BLFSBioLife Solutions Announces Pricing of $15.4 Million Public Offering
BOTHELL, Wash., March 20, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFS) today announced the pricing of a public offering and the entry into definitive agreements with purchasers for the sale of approximately 3.6 million units for gross proceeds to the Company of appr
Read more →BLFSBioLife Solutions Announces Sponsorship of Alliance for Regenerative Medicine 2nd Annual REGENMED Investor Day
BOTHELL, Wash., March 10, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues,
Read more →BLFSBioLife Solutions CryoStor® Freeze Media Adopted by Parcell Laboratories for Stem Cells to be Studied in Clinical Trials
BOTHELL, Wash., Feb. 25, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFSD), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues (
Read more →BLFSBioLife Solutions Announces 2013 Full Year Results Driven by Product Adoption in Regenerative Medicine
BOTHELL, Wash., Feb. 12, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFSD), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues (
Read more →BLFSBioLife Solutions To Be Issued New Biopreservation Patent
BOTHELL, Wash., Jan. 29, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, t
Read more →BLFSBioLife Solutions Announces 1:14 Reverse Stock Split
BOTHELL, Wash., Jan. 21, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, t
Read more →BLFSBioLife Solutions Preliminary 2013 Revenue Grows to $9 Million
BOTHELL, Wash., Jan. 6, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical-grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, to
Read more →BLFSBioLife Solutions Applies to List its Common Shares on the NASDAQ Capital Market®
BOTHELL, Wash., Dec. 16, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, t
Read more →BLFSBioLife Solutions CryoStor® Adopted by Discgenics for Use in Novel, Injectable Cellular Therapy for Degenerative Disc Disease
BOTHELL, Wash., Dec. 9, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, t
Read more →BLFSBioLife Solutions Appoints Raymond W. Cohen as Chairman and Joe Schick to Board of Directors
BOTHELL, Wash., Nov. 19, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer,
Read more →BLFSBioLife Solutions Announces $2.2 million Total Revenue for the Third Quarter of 2013
BOTHELL, Wash., Nov. 14, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer,
Read more →BLFSBioLife Solutions Makes Deloitte
BOTHELL, Wash., Nov. 13, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer,
Read more →BLFSBioLife Solutions and SAVSU Technologies Announce Exclusive Distribution Agreement
BOTHELL, Wash. and SANTE FE, N.M., Sept. 23, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media products for cells and tissues, and contract
Read more →BLFSBioLife Solutions Provides Update on Clinical Use of CryoStor® and HypoThermosol® Cell and Tissue Biopreservation Media Products
BOTHELL, Wash., Sept. 3, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media products for cells and tissues, and contract aseptic media manuf
Read more →BLFSBioLife Solutions HypoThermosol® Embedded in Two Intercytex Clinical Trials of Cell-Based Wound Care
BOTHELL, Wash., Aug. 22, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer,
Read more →BLFSBioLife Solutions Expands Strategic Relationship with STEMCELL Technologies Inc.
BOTHELL, Wash., Aug. 13, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer,
Read more →BLFSBioLife Solutions Announces Record Revenue of $2.3 Million in the Second Quarter of 2013
BOTHELL, Wash., Aug. 12, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer,
Read more →BLFSBioLife Solutions Announces the Addition of Robert Preti, Ph.D. to its Scientific Advisory Board
BOTHELL, Wash., July 23, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer,
Read more →BLFSBioLife Solutions Announces Strategic Partnership with HemaCare
BOTHELL, Wash., June 25, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer,
Read more →BLFSBioLife Solutions Named One of Washington
BOTHELL, Wash., June 24, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTC:BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, tod
Read more →BLFSBioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress
BOTHELL, Wash., May 23, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTC:BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, toda
Read more →BLFSBioLife Solutions Announces Record Revenue of $2.2 Million in First Quarter of 2013
BOTHELL, Wash., May 14, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, t
Read more →BLFSBioLife Solutions Announces Participation and Additional Product Citations at 19th ISCT Annual Meeting
BOTHELL, Wash., May 6, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, to
Read more →BLFSBioLife Solutions Announces License Agreement
BOTHELL, Wash., May 2, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, to
Read more →BLFSBioLife Solutions Announces 2012 Full Year Results; 10th Consecutive Quarter of Record Revenue
BOTHELL, Wash., April 1, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer,
Read more →BLFSBioLife Solutions Appoints Rick Stewart To Board of Directors
BOTHELL, Wash., Feb. 4, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract media manufacturer, today ann
Read more →BLFSDHI Global Medical Group Adopts BioLife Solutions
BOTHELL, Wash., Jan. 8, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract media manufacturer, today ann
Read more →BLFSBioLife Solutions Reports Preliminary 2012 Revenue at $5.7 Million; Doubled from 2011
BOTHELL, Wash., Jan. 7, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract media manufacturer, today ann
Read more →BLFSBioLife Solutions To Present at OneMedForum 2013
BOTHELL, Wash., Jan. 2, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract media manufacturer, today ann
Read more →BLFSBioLife Solutions Announces TiGenix
BOTHELL, Wash., Dec. 12, 2012 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract media manufacturer, today an
Read more →BLFSBioLife Solutions Announces 2012 Third Quarter Results: Ninth Straight Quarter of Record Revenue
BOTHELL, Wash., Nov. 13, 2012 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer,
Read more →BLFSBioLife Solutions Products Now Used in More than 50 Clinical Trial-Stage Cellular Therapies
BOTHELL, Wash., Oct. 29, 2012 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer,
Read more →BLFSBioLife Solutions Secures Exclusive Distribution Rights For Cellenergy™ Hair Graft Storage Additive
BOTHELL, Wash., Oct. 17, 2012 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer,
Read more →BLFSBioLife Solutions Announces Presentation at IBC Inaugural Cell Therapy Clinical Development Conference
BOTHELL, Wash., Sept. 12, 2012 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer,
Read more →BLFSBioLife Solutions Announces 2012 Second Quarter Results: Eighth Straight Quarter of Record Revenue
BOTHELL, Wash., Aug. 14, 2012 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer,
Read more →BLFSBioLife Solutions Completes Corporate Facilities Expansion, Build-Out of Additional cGMP Clean Room Manufacturing Suite
BOTHELL, Wash., July 23, 2012 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract media manufacturer, today an
Read more →BLFSBioLife Solutions Completes First $1 Million Revenue Quarter
BOTHELL, Wash., July 9, 2012 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract media manufacturer, today ann
Read more →BLFSBioLife Solutions Restructures Term Debt; Secures 3-Year Extension on Maturity
BOTHELL, Wash., June 1, 2012 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract media manufacturer, today ann
Read more →BLFSBioLife Solutions Announces 7th Consecutive Quarter of Record Revenue
BOTHELL, Wash., May 14, 2012 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, t
Read more →BLFSBioLife Solutions Announces Record 4th Quarter and Full Year 2011 Financial Results and Provides 2012 Outlook
BOTHELL, Wash., March 26, 2012 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer,
Read more →BLFSBioLife Solutions Commences Build-Out of Second GMP Production Suite and Corporate Office Expansion
BOTHELL, Wash., March 5, 2012 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, today announced that it has executed an a
Read more →BLFSImproved Cord Blood Processing Research on BioLife Solutions CryoStor® Published in TRANSFUSION
BOTHELL, Wash., Feb. 17, 2012 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, today announced that TRANSFUSION, the for
Read more →BLFSBioLife Solutions Congratulates DCPrime on Its Approved Orphan Medicinal Product Application for DCOne™ Leukemia Vaccine
BOTHELL, Wash., Feb. 6, 2012 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, today recognized its customer DCPrime, a D
Read more →BLFSIndependent Data Published on BioLife Solutions HypoThermosol® and CryoStor®
BOTHELL, Wash., Jan. 27, 2012 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer, and marketer of proprietary hypothermic storage and cryopreservation freeze media for cells and tissues, today announced that several groups of independent rese
Read more →BLFSBioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board
BOTHELL, Wash., Jan. 23, 2012 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer, and marketer of proprietary hypothermic storage and cryopreservation freeze media for cells, tissues, and organs, today announced that three additional key opin
Read more →BLFSBioLife Solutions 2011 Revenue Up 33%
BOTHELL, Wash., Jan. 10, 2012 /PRNewswire/ -- BioLife Solutions Inc. (OTCBB: BLFS), a leading developer, manufacturer, and marketer of proprietary hypothermic storage and cryopreservation freeze media for cells and tissues, today announced preliminary record revenue for the fourt
Read more →BLFSBioLife Solutions Launches Search Engine Optimized Website and 1,000 Free Samples Offer
BOTHELL, Wash., Dec. 6, 2011 /PRNewswire/ -- BioLife Solutions Inc. (OTCBB: BLFS), a leading developer, manufacturer, and marketer of proprietary biopreservation media products for cells, tissues, and organs, today announced the launch of its new corporate website that includes t
Read more →BLFSBioLife Solutions Q3 2011 Revenue Up 36 Percent Year over Year at $715,000; Up 15 Percent Over Q2 2011
BOTHELL, Wash., Oct. 3, 2011 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer and manufacturer of clinical grade biopreservation media products for cells and tissues and contract media manufacturer, today announced preliminary record revenue of $715,000
Read more →BLFSBioLife Solutions Reports Record Quarterly Revenue
BOTHELL, Wash., July 6, 2011 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer and manufacturer of clinical grade biopreservation media products for cells and tissues, today announced preliminary revenue of $623,000 for its second quarter ended June 30, 2
Read more →BLFSBioLife Solutions Now The Leading Supplier of Pre-Formulated GMP Cryopreservation Media for Umbilical Cord Blood Stem Cells
BOTHELL, Wash., June 21, 2011 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer and manufacturer of clinical grade biopreservation media products for cells and tissues, today announced that it has become the leading supplier of pre-formulated GMP cryopres
Read more →BLFSBioLife Solutions Announces Record Quarterly Revenue
BOTHELL, Wash., April 6, 2011 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer and manufacturer of clinical grade biopreservation media products for cells and tissues, today announced preliminary revenue of $611,000 for its first quarter ended March 31,
Read more →BLFSBioLife Solutions Increases 2011 Financial, Scientific, Technical Support of the Regenerative Medicine Industry
BOTHELL, Wash., Jan. 18, 2011 /PRNewswire/ -- BioLife Solutions, Inc. (OTC Bulletin Board: BLFS) announced today that it has significantly increased its financial support for several key organizations in the regenerative medicine industry. The worldwide regenerative medicine mark
Read more →Competitive Position
How BLFS ranks across every disease it competes inCompetitive Position is a premium feature
See how BLFS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial